<DOC>
	<DOCNO>NCT01329016</DOCNO>
	<brief_summary>This pharmacokinetic pharmacodynamic study evaluate glyburide , metformin , combination treatment gestational diabetes mellitus .</brief_summary>
	<brief_title>Glyburide Metformin Gestational Diabetes Mellitus ( GDM )</brief_title>
	<detailed_description>Gestational diabetes mellitus ( GDM ) common complication pregnancy . Multiple treatment regimens currently use management GDM . Following failure diet therapy , insulin , glyburide metformin use treatment GDM oral medication provide comparable outcome insulin easy route administration schedule . The propose work evaluate pharmacokinetics ( PK ) pharmacodynamics ( PD ) glyburide metformin alone combination order lay foundation establish dosage response information could utilize design phase III randomize trial ultimately evaluate GDM treatment optimization .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Gestational Diabetes Subject Selection 1 . Pregnant woman ( singleton pregnancy ) 2 . Gestational diabetes mellitus 3 . Able give write informed consent 4 . Drug treatment require GDM 5 . Gestational age 2032 week Gestational diabetes diagnosis must occur 20 week prior 32 week gestation Randomization treatment initiation must occur later 32 week gestation 6 . Willing avoid ethanol 7 . 1845 year age Type 2 Diabetes Mellitus Subject Selection 1 . Able give write informed consent 2 . New diagnosis type 2 diabetes mellitus 3 . Plan receive metformin treatment type 2 diabetes mellitus 4 . 1845 year age 5 . Female 6 . Negative pregnancy test 7 . Hemoglobin A1C &gt; 7 % Healthy Pregnant Women 1 . Able give write informed consent 2 . Pregnant woman ( singleton ) 3 . Normal 1hour glucose tolerance test 4 . 2032 week gestation 5 . 1845 year age Neonates : All infant pregnant woman participate study include Women GDM T2DM 1 . Women take medication expect interact glyburide , metformin alter blood glucose concentration 2 . Serum creatinine &gt; 1.2 mg/dL 3 . Hematocrit &lt; 28 % 4 . Allergy glyburide , metformin sulfa 5 . Significant hepatic disease 6 . Congestive heart failure history MI 7 . Moderate severe pulmonary disease 8 . Adrenal pituitary insufficiency Healthy Pregnant Women 1 . Receiving hypoglycemic agent 2 . Receiving corticosteroid 3 . Known kidney , liver , heart , pulmonary , adrenal pituitary disease 4 . Hematocrit &lt; 28 % Neonates 1 . Infants viable ill blood sample collection include clinical outcome data collection , exclude research activity . 2 . Infants &lt; 1.5 kg include clinical outcome data collection , exclude blood sample collection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Glyburide</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>